In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that a Post Grant Review petition filed against one of its key U.S. patents has been withdrawn. The decision leaves no remaining challenges pending against the company’s U.S. Patent No. 12,138,276, a patent covering halogenated psilocybin derivatives.
